Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea.
Kim ES, Park SK, Cho DS, Youn JC, Lee HS, Lee HY, Cho HJ, Choi JO, Jeon ES, Lee SE, Kim MS, Kim JJ, Hwang KK, Cho MC, Chae SC, Kang SM, Park JJ, Choi DJ, Yoo BS, Cho JY, Kim KH, Oh BH, Greenberg B, Baek SH.
Kim ES, et al. Among authors: jeon es.
Am J Cardiovasc Drugs. 2024 Mar;24(2):313-324. doi: 10.1007/s40256-024-00632-w. Epub 2024 Feb 27.
Am J Cardiovasc Drugs. 2024.
PMID: 38413500